Abstract
A prominent degeneration of dopaminergic (DA-ergic) neurons in basal ganglia (striatum and substantia nigra) and a profound loss of dopamine resulting in patient motor dysfunctions are the main characteristics of Parkinson's disease (PD). The data available indicate a substantial role of nicotinic acetylcholine receptors (nAChR) in molecular mechanisms underlying PD. nAChRs belong to the superfamily of ligand-gated ion channels, their pharmacological profile being determined by an array of subunits forming a distinct receptor subtype. Acetylcholine modulates dopamine release via an interaction with multiple nAChRs subtypes present on the nigrosriatal neurons. This suggests nAChRs as possible targets in the treatment of PD, however the knowledge of subunit composition is necessary for effective drug design. As studies in humans are quite limited, animal models are broadly used for these purposes. For creating experimental Parkinsonism models, low molecular weight toxic organic compounds are commonly used. 1-Methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine (6-OHDA), 1,1'-Dimethyl-4-4'-bypiridinium dichloride (paraquat), pesticide rotenone and ubiquitin proteasome system inhibitors, such as lactacystin and epoxomicin, can be mentioned as applied more often. Both mammalian and non-mammalian animals are used as model organisms, rodent and non-human primates being used mainly as mammalian models. This review summarizes the data obtained on toxic animal models about the involvement of different nAChR subtypes in PD at different stages. The present data suggest that degeneration of nigrostriatal DA-ergic neurons in the animal PD models is accompanied by alterations in the expression level and functional activity of different nAChR subtypes. Both heterooligomeric α6- and/or α4-containing and α7 homooligomeric subtypes are affected and can be regarded as possible targets for intervention.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.